Posts tagged Jason Wittes


Brean Capital Reiterates Buy on Celldex Therapeutics, Inc. (CLDX) Following Phase II Results in Refractory Melanoma

In a research report published Monday, Brean Capital analyst Jason Wittes reiterated a Buy rating …

Read more

Brean Capital Assumes Buy on Inovio Pharmaceuticals Inc (INO); Sees 9% Upside for the Stock

In a research report released Tuesday, Brean Capital analyst Jason Wittes assumed coverage on shares of …

Read more

Brean Capital Assumes Buy on Celldex Therapeutics, Inc. (CLDX); Sees 265% Upside for the Stock

Brean Capital analyst Jason Wittes was out with a research report, assuming coverage on shares of Celldex Therapeutics, Inc. …

Read more

Brean Capital Assumes Buy on Progenics Pharmaceuticals, Inc. (PGNX); Sees 50% Upside for the Stock

In a research report published Tuesday, Brean Capital analyst Jason Wittes assumed coverage on shares of …

Read more

Here’s Why Brean Capital Downgraded Osiris Therapeutics, Inc. (OSIR) to Sell

In a research report released Tuesday, Brean Capital analyst Jason Wittes downgraded shares of Osiris Therapeutics, …

Read more

Brean Capital Maintains Buy NuVasive Following Preliminary 4Q14 Results

In a research report issued today, Brean Capital analyst Jason Wittes maintained a Buy rating on …

Read more